Tazocin Adverse Reactions

Adverse reactions are listed in CIOMS frequency categories: Very common: ≥10%; common: ≥1%; uncommon: ≥0.1% and <1%; rare: ≥0.01% and <0.1%; very rare: <0.01%.
Infections and Infestations: Uncommon: Candidal superinfection.
Blood and Lymphatic System: Uncommon: Leukopenia, neutropenia, thrombocytopenia. Rare: Anemia, bleeding manifestations (including purpura, epistaxis and prolonged bleeding time), eosinophilia, haemolytic anemia. Very Rare: Agranulocytosis, positive Coombs' direct test, pancytopenia, prolonged partial thromboplastin time, prolonged prothrombin time, thrombocytosis.
Immune System Disorders: Uncommon: Hypersensitivity reaction. Rare: Anaphylactic/anaphylactoid reaction (including shock).
Metabolism and Nutrition Disorders: Very Rare: Decreased blood albumin, decreased blood glucose, decreased total blood protein, hypokalemia.
Nervous System Disorders: Uncommon: Headache, insomnia.
Vascular System Disorders: Uncommon: Hypotension, phlebitis, thrombophlebitis. Rare: Flushing.
Gastrointestinal System Disorders: Common: Diarrhea, nausea, vomiting. Uncommon: Constipation, dyspepsia, jaundice, stomatitis. Rare: Abdominal pain, pseudomembranous colitis.
Hepatobiliary System Disorders: Uncommon: Increased alanine aminotransferase, increased aspartate aminotransferase. Rare: Increased bilirubin, increased blood alkaline phosphatase, increased γ-glutamyltransferase, hepatitis.
Skin and Subcutaneous Tissue Disorders: Common: Rash. Uncommon: Pruritus, urticaria. Rare: Bullous dermatitis, erythema multiforme. Very Rare: Stevens-Johnson syndrome, toxic epidermal necrolysis.
Musculoskeletal, Connective Tissue and Bone Disorders: Rare: Arthralgia.
Renal and Urinary System Disorders: Uncommon: Increased blood creatinine. Rare: Interstitial nephritis, renal failure. Very Rare: Increased blood urea nitrogen.
General Disorders and Administration Site Conditions: Uncommon: Fever, injection site reaction. Rare: Rigors.
Piperacillin therapy has been associated with an increased incidence of fever and rash in cystic fibrosis patients.